Graham Pechenik Profile picture
IP law & strategy for cannabis & psychedelics ventures | Registered patent attorney | UCSD biochem+cog neuroscience | NYU Law | SF/Oakland native
Jan 19, 2023 8 tweets 3 min read
What happens when two companies’ patents both cover the same drug?

Reunion Neuroscience’s lead RE104 = isoprocin glutarate, a prodrug of 4-OH-DiPT

Reunion $REUN has a granted patent claiming it

Today, Mindset Pharma $MSET received a notice of allowance on claims to it too

1/7 Field Trip $FTRP (the original applicant) obtained its patent on RE104 (then FT-104) after first w/drawing it from issuance to ensure examiner reviewed Mindset’s apps

Mindset’s were filed first, but only published after Field Trip’s app was allowed

Patent was allowed again

2/7
Jun 22, 2022 9 tweets 5 min read
MDMA + LSD = a patentable invention?

According to the USPTO, yes

Today—MindMed $MNMD granted a US patent, with claims to:

“A composition comprising an empathogen/entactogen and a psychedelic in the same single oral dosage form.”

Along with methods of using it

🍬🤸🏻

1/9 What’s the patentable invention?

According to MindMed, that the entactogen & the psychedelic are in “the same single oral dosage form”

By contrast: “Recreational users use MDMA & LSD in separate dosage forms.”

A single dosage form ≠ “a single session of substance abuse”

2/x
Feb 2, 2022 6 tweets 5 min read
All your vapes are belong to us?

New patent granted—“Delivery System for Ayahuasca-Like Substances”

Claims DMT vapes, 5-MeO-DMT vapes, & 2C-B vapes

These claims can be immediately enforced

1/6 The patent claims:

“A device for the delivery of a substance comprising:

a chamber comprising at least one vaporizable formulation wherein the vaporizable formulation comprises the substance and wherein the substance comprises one or more of”

DMT, 5-MeO-DMT, or 2C-B

2/6
Dec 31, 2021 4 tweets 4 min read
Patentable pharmahuasca “kits of parts”?

New PCT app published: “Compositions & Kits of Parts Comprising N,N-DMT & Harmine & Their Use in Therapy”

“An alternative to ayahuasca that solves the problems of side effects…is pharmahuasca, also known as synthetic ayahuasca”

1/4 Applicant is University of Zürich, w inventors Dario Dornbierer, Davor Kosanic, & Milan Scheidegger

All are founders at Reconnect Labs: “a Spin-off of the University of Zürich…setting standards for a novel kind of ethical drug development company”

reconnect-foundation.org/reconnect-labs/

2/4
Dec 30, 2021 9 tweets 8 min read
New psychedelic inventions?

∰ Field Trip—tryptamine prodrugs

∰ Greenway DNA—personalized psychedelic treatment

∰ Small Pharma—deuterated DMT

1/9
Field Trip $FTRP: “Tryptamine Prodrugs”

Application covers diacid hemiester prodrugs of tryptamines & isotryptamines, eg, psilocin, 4-HO-DET, 4-HO-DiPT, & 4-HO-MiPT

Head twitch response & pharmacokinetics in rats & humans with 4-hemiglutarate & 4-hemisuccinate of 4-HO-DiPT

2/9
Dec 29, 2021 14 tweets 13 min read
New psychedelic inventions?

⁂ Phil Wolfson/KRF—ketamine for postpartum symptoms

⁂ Psilo Scientific—psychoactive & psychedelic fungus extraction

⁂ Cognigenics—5-HT2A “cognitive upgrade”

⁂ Liechti—MDMA response prediction

⁂ Small Pharma—DMT-type compound synthesis

1/14 …and more new psychedelic inventions?

⁂ Ixtlan—psilocybin for Alzheimer’s

⁂ Spirify—hydroxynorketamine analogs

⁂ Guangzhou Dazhou Biomedicine—transdermal ketamine

⁂ Disruption Labs—nanoparticle compositions

⁂ Daniel Lilly—“medicinal food products” with psilocybin

2/14
Nov 20, 2021 6 tweets 5 min read
Novel ketamine + psilocybin inventions?

New patent applications published:

𝔎 Celon Pharma—pulmonary administration of ketamine

𝔎 Univ Kansas—ketamine treatment for ALS

𝔎 Takeda Pharm—depression tx, after ketamine therapy

𝔎 CaaMTech—combinations of serotonergic drugs

1/6
Celon Pharma—“Ketamine Composition for Use in a Method of Treatment of Depression by Pulmonary Administration”

–inhalable dry powder ketamine compositions

–dosage regimens for their use “in a cycle of administrations of sequences of single doses”

appft.uspto.gov/netacgi/nph-Pa…

2/6
Nov 18, 2021 12 tweets 5 min read
Ibogaine + MDA = “an extremely beneficial drug”?

#TBT to 1968 patents by Claudio Naranjo

“The medical preparation of the invention produces most unexpected and beneficial results, by for example alleviating fears and anxieties which may have been present in the patient”

1/12 Image The patents claimed medical preparations of:

(1) ibogaine, iboga alkaloid extract, or total extract; plus

(2) amphetamine, MDA, TMA, tetrahydronapthylamine, or naphazoline

“The best results have been obtained with” MDA

The combination “forms an excellent medicine"

2/12 ImageImage
Mar 21, 2021 7 tweets 4 min read
New Compass Pathways patents granted?

Another US patent was granted on March 16, 2021

This is Compass’ second US patent, in same family as the first patent granted on December 31, 2019

New ‘257 patent: patft.uspto.gov/netacgi/nph-Pa…

First ‘175 patent: patft.uspto.gov/netacgi/nph-Pa…

1/7 A primary difference between the new ‘257 & the first ‘175 patent is:

– ‘175 patent claims methods “of treating drug resistant depression” by orally administering “an oral dosage form“ of the COMP360 psilocybin Polymorph A

– ‘257 patent claims the “oral dosage form” itself

2/7
Mar 20, 2021 7 tweets 4 min read
Who will own psilocybin for anorexia?

One of the methods claimed in Compass’ PCT application is administering “a therapeutically-effective dose of psilocybin” to a subject with anorexia

Could a claim on treating anorexia with psilocybin be granted?

1/7 Compass is listed as collaborator on an investigator-initiated study at UC San Diego, to explore the safety, tolerability, & efficacy of psilocybin-assisted therapy for anorexia

This trial was first posted on December 10, 2020

2/7

clinicaltrials.gov/ct2/show/NCT04…
Feb 18, 2021 4 tweets 3 min read
How much is a psilocybin patent application worth?

PharmaTher $PHRM sells psilocybin program to Revive Therapeutics $RVV

Includes full rights to PharmaTher’s psilocybin IP:

Pre-clinical work + three psilocybin provisional applications

1/4 Purchase price for PharmaTher’s psilocybin IP:

–$3 million in cash

–$4 million in securities

–up to $3 million in milestone payments

–“low single digit royalty” on future net sales

2/4
Feb 17, 2021 4 tweets 3 min read
“Emergency Off-Switch” for psychedelics?

MindMed $MMED beings study on “LSD neutralizer technology”

I.e., the 5-HT2A antagonist ketanserin: psychedelicreview.com/compound/ketan…

1/4 Patent application first announced on April 21, 2020

As @psyscireview subsequently wrote: “Few Details of the Invention Are Available”

18 months after filing, the application—& those details—will become public

~ October 2021

psychedelicreview.com/stopping-bad-l…

2/4
Feb 16, 2021 6 tweets 4 min read
Controlled release psilocybin + cannabinoid formulations?

New published patent application on multilayer tablets & capsules w psilocybe-derived + cannabis-derived compounds

Filed by Tassili Life Sciences, acquired last yr by Champignon Brands

patentscope.wipo.int/search/en/deta… $SHRM

1/ ImageImageImage Application claims compositions of “psilocybe-derived agent and a cannabis-derived agent”

”formulated in multiple layers to release the psilocybin-derived agent and the cannabis-derived agent at multiple different times, dosages and/or locations in a subject during dosing”

2/ Image
Dec 23, 2020 9 tweets 4 min read
Canopy Growth sues GW Pharmaceuticals:

Complaint for patent infringement filed on 12/22 in Texas

“This dispute relates to GW’s continued, unauthorized use of Canopy’s patented processes for extracting cannabidiol from cannabis plant material.”

1/

$CGC $GWPH #cannabispatents Canopy alleges infringement of one patent:

US Patent No. 10,870,632 “Process For Producing An Extract Containing Tetrahydrocannabinol And Cannabidiol From Cannabis Plant Material, And Cannabis Extracts”

Patent issued 12/22—same day complaint filed

pdfpiw.uspto.gov/.piw?Docid=108…

2/
Dec 17, 2020 9 tweets 5 min read
Deuterated DMT analogs?

New patent application by Small Pharma published today.

The “invention provides compositions and methods which enable a finely tuned single dose to maintain a patient in full dissociation from the external world, referred to herein as ‘DMT space.’”

1/ Image In particular, the invention takes advantage of “the kinetic isotope effect” exhibited by deuterated DMT analogs “in order to modify, controllably, the pharmacokinetic profile of N,N-DMT, thereby permitting more flexible therapeutic application.”

pdfaiw.uspto.gov/.aiw?PageNum=0…

2/ Image